PROMETHEUS BIOSCIENCES INC (RXDX)       108.68  +0.25 (+0.23%)

108.68  +0.25 (+0.23%)

US74349U1088 - Common Stock - After market: 108.68 0 (0%)


Fundamental Rating

3

Overall RXDX gets a fundamental rating of 3 out of 10. We evaluated RXDX against 640 industry peers in the Biotechnology industry. RXDX has a great financial health rating, but its profitability evaluates not so good. RXDX is quite expensive at the moment. It does show a decent growth rate.

Note: RXDX has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

RXDX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of RXDX.

VS Industry

Valuation

Valuation Rating

0

RXDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXDX. No positive earnings are expected for the next year.

With a price book ratio of 21.68, RXDX is valued rather expensively.
When comparing the price book ratio of RXDX to the average industry price book ratio of 1.89, RXDX is valued more expensive than its industry peers. 97% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (21.68) VS Industry: 3% outperformed.

448.49
0.07

Growth

Growth Rating

4

The Revenue has grown by 154.39% in the past year. This is a very strong growth!
RXDX is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 143.87% yearly.

RXDX is expected to show a decrease in Earnings Per Share. In the coming 5 years, the EPS will decrease by -5.49% yearly.
RXDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -188.70%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -188.7% 2.14% -1.43% -4.83% -5.49%
RevenueN/A N/A 154.39% 157.66% -8.61% -0.13% 143.87%

Health

Health Rating

7

RXDX has a Current Ratio of 11.19. This indicates that RXDX is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of RXDX is much better than the industry average of 6.21.
A Quick Ratio of 11.19 indicates that RXDX has no problem at all paying its short term obligations.
RXDX is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.11.

An Altman-Z score of 43.82 indicates that RXDX is not in any danger for bankruptcy at the moment.
The Altman-Z score of RXDX is much better than the industry average of 0.01. RXDX has a better rating than 97% of its industry peers.
The Debt to Equity ratio of RXDX is in line with the industry averages.
RXDX has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of RXDX.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (11.19) VS Industry: 75% outperformed.

0.04
84.53

Current Ratio (11.19) VS Industry: 75% outperformed.

0.08
85.09

Altman-Z (43.82) VS Industry: 97% outperformed.

-94.26
670.27

Dividend

Dividend Rating

0

RXDX does not give a dividend.

PROMETHEUS BIOSCIENCES INC108.68

NASDAQ:RXDX (2/3/2023, 3:30:02 PM)+0.25 (+0.23%)

After market: 108.68 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) N/A N/A
Inst Owners 72.05% Inst Owner Change -0.1%
Ins Owners 0.2% Ins Owner Change 62.08%
Market Cap 5.04B Analysts 88.24
Price Target 149.1 (37.19%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 5.06%
Min EPS beat(2) 2.44% Max EPS beat(2) 7.69%
EPS beat(4) 2 Avg EPS beat(4) -0.64%
Min EPS beat(4) -11.3% Max EPS beat(4) 7.69%
Revenue beat(2) 2 Avg Revenue beat(2) 95.82%
Min Revenue beat(2) 47.9% Max Revenue beat(2) 143.73%
Revenue beat(4) 4 Avg Revenue beat(4) 191.04%
Min Revenue beat(4) 47.9% Max Revenue beat(4) 485.54%
PT rev (1m) 1.84% PT rev (3m) 129.06%
EPS NQ rev (1m) 0% EPS NQ rev (3m) 2.05%
EPS NY rev (1m) 0% EPS NY rev (3m) 1.01%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) 2.01%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 11.95%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 700.97
P/FCF N/A
P/OCF N/A
P/B 21.68
P/tB 21.68
EV/EBITDA N/A
EPS(TTM) -3.35 EY N/A
EPS(NY) -3.73 Fwd EY N/A
FCF(TTM) -2.3 FCFY N/A
OCF(TTM) -2.25 OCFY N/A
SpS 0.16 BVpS 5.01
TBVpS 5.01 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover 0.02

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 502.79%
Profit Quality N/A
Current Ratio 11.19
Quick Ratio 11.19
Altman-Z 43.82
F-Score 3 WACC 8.95%
ROIC/WACC N/A Cap/Depr(3y) 440.71%
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -188.7% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -28.57%
EPS Next Y 2.14% EPS Next 2Y -1.43%
EPS Next 3Y -4.83% EPS Next 5Y -5.49%
Revenue growth 1Y 154.39% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q -3.78%
Revenue Next Year 157.66% Revenue Next 2Y -8.61%
Revenue Next 3Y -0.13% Revenue Next 5Y 143.87%
EBIT growth 1Y -202.66% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year -68.07%
EBIT Next 3Y -36.39% EBIT Next 5Y N/A
FCF growth 1Y -129.06% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -126.64%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA